Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 1999, and the nine-month period ended on the same date for Becton, Dickinson and Company (BD). BD is a global medical technology company headquartered in Franklin Lakes, New Jersey. The report details financial performance, significant restructuring activities, and strategic acquisitions.
Key Financial Metrics
| Metric | Three Months Ended June 30, 1999 | Nine Months Ended June 30, 1999 |
|---|---|---|
| Revenues | $873.0 million | $2,515.9 million |
| Net Income | $33.1 million | $199.4 million |
| Diluted EPS | $0.12 | $0.75 |
| Operating Income | $53.5 million | $308.8 million |
| Gross Profit Margin | 47.2% | 49.3% |
| Net Cash from Operating Activities | N/A | $306.2 million |
| Total Debt (Short + Long Term) | $1.352 billion | $1.352 billion |
| Cash and Equivalents | $67.0 million | $67.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 5% in the third quarter and 11% for the nine-month period compared to the prior year. Growth was driven by acquisitions and strong international performance, partially offset by underperformance in the home healthcare business and a stronger U.S. dollar.
- Profitability: Net income improved significantly from a loss of $10.0 million in the prior year's third quarter to a profit of $33.1 million. Operating income rose from $8.3 million to $53.5 million.
- Special Charges: The company recorded $75.6 million in special charges for the quarter, primarily due to the exit of certain product lines (home healthcare self-monitoring), asset write-downs, and a voluntary retirement incentive program. This compares to $90.9 million in charges in the prior year quarter.
- Acquisitions: BD acquired five businesses in the first nine months of 1999 for a net purchase price of $153.2 million. Additionally, a revised agreement was signed in August 1999 to acquire Clontech Laboratories, Inc. for $200 million.
- Debt and Liquidity: Total debt increased to $1.352 billion (up from $1.150 billion at the prior year-end) to fund acquisitions. Cash and equivalents decreased to $67.0 million from $83.3 million.
Guidance, Outlook, and Risks
- Outlook: Management expects full-year capital expenditures to be approximately $275 million. The company anticipates a full-year income tax rate of about 25%, reflecting a favorable tax judgment in Brazil and a favorable mix of income among jurisdictions.
- Year 2000 Readiness: BD has substantially implemented its Year 2000 plan. As of August 1, 1999, approximately 98% of remediation and testing for products with date-sensitive technology was complete. The estimated total cost of the plan is $16 million, with $10 million incurred by June 30, 1999.
- Legal Contingencies: The company is a defendant in approximately 280 product liability lawsuits related to natural rubber latex and 11 lawsuits regarding accidental needle sticks. Management does not expect these matters to have a material impact on financial results.
- Restructuring: Implementation of exit plans for exited product lines is expected to be completed by the latter part of fiscal year 2000.
Investor Verification Checklist
- Special Charges Impact: Verify the non-recurring nature of the $75.6 million in special charges and the specific impact on the home healthcare segment's future revenue stream.
- Clontech Acquisition: Confirm the closing of the $200 million Clontech Laboratories acquisition and the associated purchase accounting implications.
- Year 2000 Costs: Monitor the final costs of the Year 2000 remediation plan against the $16 million estimate and watch for any third-party claims arising from compliance failures.
- Debt Levels: Assess the sustainability of the increased debt load ($1.35 billion) relative to operating cash flows, particularly given the $153 million in recent acquisition spending.
- Latex Litigation: Track the status of the coordinated latex glove product liability litigation (MDL Docket No. 1148) for any changes in the estimated liability.